Clinical Trial Agreement Course

The greatest attention when negotiating clinical trial budgets and contracts focuses on fair remuneration for conducting clinical research. However, experience has shown that the highest risk of these negotiations is not Good Clinical Practice (GCP), which can result in high fines and fines for the unwary. This webinar will clarify these rules and rules and give practical instructions on how to safely navigate these waters. To learn more about this course on designing and negotiating agreements for clinical trials, simply fill in your data: early Bird fees are available up to 21 days before the course starts. The course is aimed at contract managers, lawyers and project managers who have been in contact with CTAs, but who are not experts and do not have several years of experience in the trial. We find that participants are primarily based in universities, hospitals, and life science companies, including CROs. Mark has nearly 30 years of experience in developing, negotiating and advising contracts for life sciences companies and universities, including CTAs. He is editor-in-chief of Drafting Agreements in the Biotechnology and Pharmaceutical Industries (OUP lose leaf since 2008). He has a long experience in the assignment of courses in CTAs. For several years, he has been recommended by Chambers Directory as a national expert in life science transactions and for patent licensing by IAM Patent 1000. His 5-day course on IP transactions, organized by UCL with about thirty volunteer speakers, won both a Highly Commended Award of Excellence and a Provost`s Teaching Award.

If you have any questions about this course, please email Lisa Penfold of the UCL Faculty of Laws for lisa.penfold@ucl.ac.uk 09:30 Introduction to today`s course; problems that generally arise; The regulatory framework (UK and EU) and the impact on CTS. . . . . .